CellCarta and Imagene AI expanded their partnership to bring AI pathology into a more end-to-end path for NSCLC companion diagnostics. The companies said the collaboration covers assay validation, clinical deployment, regulatory support, and program coordination, aiming to move AI-derived biomarkers from algorithm into globally deployable testing. The effort includes AI-powered biomarker programs using both immunohistochemistry (IHC) quantification and hematoxylin and eosin (H&E)-based prediction in non-small cell lung cancer, with the partners citing prior evidence of real-world utility for H&E imaging models. For biotech teams developing CDx strategies, the announcement highlights a recurring commercialization bottleneck: translating model outputs into regulator-ready assays that can survive multi-site variability and patient workflow constraints.